Form 4: Century Therapeutics CSO Reports Stock Withholding

Chief Scientific Officer Chad Cowan reported the withholding of 358 shares to satisfy tax obligations upon RSU vesting.

Summary

• Chad Cowan, Chief Scientific Officer of Century Therapeutics, Inc., executed a transaction on June 11, 2026.
• The transaction involved the withholding of 358 shares of common stock at a price of $2.24 per share.
• The withholding was conducted to satisfy tax obligations related to the vesting of restricted stock units.
• Following this transaction, the reporting person maintains direct ownership of 1,175,322 shares and indirect ownership of 10,697 shares via a trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing with no impact on company strategy or financial outlook.

Positives

• The transaction is a routine administrative action related to tax withholding rather than a discretionary market sale.

Negatives

• None identified; this is a standard regulatory disclosure for executive compensation tax compliance.

Risks

• None identified; this filing pertains to internal tax compliance and does not reflect operational or market risks.

Future Outlook

Not applicable; this is a historical disclosure of a completed transaction.

Industry Context

StockSavvy.ai notes that routine tax withholding filings are standard practice in the biotechnology sector, where equity-based compensation is a primary component of executive remuneration packages.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for publicly traded biotech firms regarding RSU vesting and tax compliance.

Stakeholder Impact

• Minimal impact; the transaction reflects standard tax settlement for executive equity awards.

Next Steps

• No further actions required by the reporting person regarding this specific transaction.

Key Dates

Keywords

Century Therapeutics, IPSC, Form 4, Insider Trading, Biotech, Executive Compensation